glp-1 agonist alcohol IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target Searching for New Pharmacological Treatments
Description
Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease
Competitive Position Summary Orforglipron occupies a unique competitive position as the first oral non-peptide GLP-1 agonist approaching approval
These results were even greater than those recorded in CVOTs
Acute kidney injury in diabetes mellitus
Like pretzels
doi: 10.1038/ncb951
